SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Fundamental Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: E_K_S who wrote (4715)7/29/2025 7:10:08 PM
From: E_K_S  Read Replies (1) of 4719
 
  • Exelixis ( EXEL, Financial) reported a 19% increase in Q2 revenue, driven by the growth of its cabozantinib franchise. The company highlighted new indications for cabozantinib and progress in its zanzalintinib pipeline. Exelixis reiterated its full-year financial guidance, with total Q2 revenues of approximately $568 million, including $520 million from the cabozantinib franchise.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News